CTIS.eu › Cities › France › Montpellier Cedex 5
Montpellier Cedex 5
France
830 total trials
379 recruiting
2024-512733-32-00
5
2025-03-31
Acute Myeloid Leukemia (AML)
2024-511346-39-00
3
2025-03-28
Immune-mediated necrotizing myopathy
2024-512536-29-00
4
2025-02-28
Amyotrophic Lateral Sclerosis (ALS)
2024-519132-17-00
4
2025-01-29
NON-METASTATIC UNRESECTABLE INTRA-HEPATIC CHOLANGIOCARCINOMA
2024-513077-48-00
5
2024-12-19
O6-methylguanine methyltransferase (MGMT) unmethylated glioblastoma
2023-507633-21-01
5
2024-12-09
Multiple Sclerosis
2024-519113-59-00
4
2024-11-20
Hepatocellular carcinoma
2024-517099-39-00
4
2024-11-18
Newly diagnosed transplant ineligible multiple myeloma
2024-514799-42-00
4
2024-11-05
IDIOPATHIC PULMONARY FIBROSIS
2024-517004-11-00
5
2024-10-22
Chronic pulmonary aspergillosis
2024-513219-29-00
5
2024-10-21
Renal Cell Carcinoma
2022-503128-29-00
10
2024-10-08
Fabry's disease
2023-504231-41-01
10
2024-10-02
Locally advanced or metastatic urothelial cancer
2023-510022-33-00
5
2024-10-02
HIV-1 infection
2024-516433-13-00
5
2024-09-19
Progressive multiple sclerosis
2024-515342-16-00
4
2024-09-05
Patients with severe and radio-induced breast fibrosis after breast ca
2024-515456-20-00
4
2024-08-13
Hepato carcinoma cancer
2023-509807-34-00
4
2024-08-12
Early Alzheimer’s Disease (Mild Cognitive Impairment and
Mild Dementi
2022-501105-12-00
5
2024-07-15
Urothelial Carcinoma
2023-507901-32-00
3
2024-06-28
Relapsed or Refractory Multiple Myeloma (R/R MM)
2023-504214-30-00
5
2024-06-27
Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
2022-502405-15-01
4
2024-04-08
Mantle Cell Lymphoma (MCL)
2023-505775-70-00
4
2024-04-08
High risk smoldering multiple myeloma
2023-508153-12-00
5
2024-03-26
Hospital-acquired pneumonia
Showing 121–144 of 830 trials